Clinical Role - Specialty Pharmacy

Pharmacy Times® is a leader in providing expert insights and clinical updates to specialty pharmacists and reaches more than 200,000 pharmacy professionals in total.

Although CDK4/6 inhibitors prolong progression-free survival for patients with ER+ breast cancer patients, the ideal treatment for each patient is currently unclear until adverse effects appear.
The study results also show improved outcomes for patients with brain metastases.
Top news of the day from across the health care landscape.
The research presented at the 2019 San Antonio Breast Cancer Symposium suggests that the different mechanisms could be exploited to overcome CDK4/6 inhibitor resistance in breast cancer patients.
The technology known as sci-Plex can analyze millions of cells to reveal how these cells may react when treated with a drug. 
Patricia Spears discusses what clinical trials can offer and when to start discussing them with patients. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.
Immunotherapy drug blinatumomab showed benefit in pediatric patients with relapsed acute lymphoblastic leukemia who have minimal residual disease following chemotherapy.
An oral formulation of azacitidine improved overall survival in patients with acute myeloid leukemia in first remission.
A combination therapy of carfilzomib, dexamethasone, and daratumumab extended progression-free survival when compared with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. 
The current observational, longitudinal study focused on patient-reported outcomes on functioning, symptoms, and quality of life in patients with chronic lymphocytic leukemia.
In a session at the American Society of Hematology Annual Meeting and Exposition, held December 7-10 in Orlando, Florida, experts presented on the evolution of CLL therapy, how to make treatment decisions, and what’s to come in the future based on ongoing studies.